This announcement is a separate document:
JCRファーマ：ムコ多糖症IIIA型に対するJR-441の第I相試験の治験計画届受理および治験計画に関する当局調査終了について
JCR Pharmaceuticals: Acceptance of clinical trial plan notifications for the JR-441 phase I trial against mucopolysaccharidosis type IIIA and completion of the agency investigation regarding the clinical trial plan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.